 Product DevelopmentThe company has 2 programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer.
>>
|
|
 Scientific ResearchPrima BioMed's technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies. >>
|
|
 Clinical TrialCVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells.
>>
|
|
Latest News
13 June 2013
Prima BioMed Ltd - Completion of Entitlement Offer >>
13 June 2013
Investor Update Edition 10 >>
23 May 2013
Ärzteblatt Sachsen: Die Autologe Immuntherapie des Ovarialkarzinoms – Eine neue Chance? // Autologous immunotherapy forovarian carcinoma – A new chance? >>
Read more news >>
Press and Video
Webcasts >>
Manufacturing of CVac >>
Interview Marc Voigt (D) >>
Interview Matt Lehman >>
Video about CVac™ >>
Channel 7 News >>
Channel 10 News >>
Channel 7 News >>
|
Connect with PrimaReceive email updates and follow us on Facebook, Twitter and on LinkedIn: | |
|
|